Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Adlai Nortye signed clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany, for the anti-EGFR antibody cetuximab (ERBITUX). Both partners will supply cetuximab at no cost — Lilly for U.S. trial sites and Merck KGaA for Australia and China sites — supporting the ongoing global Phase I trial of AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC targeting CEACAM5.
Key figures
- Drug Name
- AN4035
- Phase Of Trial
- Phase I
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.